Key Highlights

  • Emyria Limited (ASX:EMD) has recruited 31 additional therapists for its national Empax network ahead of 2027.
  • Specialised in-house Training begins on 27 November 2026 in Perth, with progressive clinical onboarding expected from CYQ1 2027.
  • Of the 31 recruits, 18 meet Therapeutic Goods Administration Lead Therapist eligibility criteria and 10 are psychologists for DVA-funded veteran treatments.
  • The company has 18 treatment beds across five sites, and states that therapist numbers, rather than beds, currently limit treatment volumes.

Emyria Limited (ASX:EMD) has recruited 31 additional therapists to support increased patient treatment capacity across its Empax network, the company announced on 19 November 2026. Emyria, which describes itself as delivering evidence-based intensive mental health care, treats patients with post-traumatic stress disorder and treatment-resistant depression who have not improved with standard care. The recruitment is intended to support the number of patients the company expects to treat in 2027.

Why Therapist Numbers Matter

The company says each treatment requires trained therapists to be present with the patient for multi-hour sessions, which means the number of trained therapists sets the number of patients Emyria can treat. Emyria has 18 treatment beds across five sites, and states that additional therapists would allow it to use those beds more fully without new Facility commitments.

Emyria says it has spent several years building the clinical infrastructure, workforce training capability and treatment protocols required to deliver its programs. The company now describes its focus as moving from establishing its national clinical infrastructure to scaling patient volumes across the network.

Composition and Training of the Recruits

Training will take place in Perth. The cohort includes 22 therapists from Perth, six from Brisbane and three from Sydney. Eighteen recruits meet the TGA Lead Therapist eligibility criteria, while ten are psychologists who will support veteran treatments funded by the Department of Veterans’ Affairs. The company says total trained therapist numbers will exceed 150 once the cohort is included.

Onboarding into clinical operations is expected from CYQ1 2027, subject to completion of training and supervised onboarding required to maintain clinical standards. The company has tied that timing to the completion of those steps rather than to a fixed date.

Revenue Pathways and Risk Disclosures

Emyria identifies three areas where the expanded workforce could support activity: reimbursed patient treatments under its PTSD and treatment-resistant depression programs, DVA-funded veteran treatments, and pharmaceutical-sponsored Clinical Trials delivered through the Empax network. The company has not provided Revenue forecasts or quantified the expected increase in patient numbers.

The announcement includes cautionary notes. It states that Emyria makes no representations about the safety or efficacy of the products it is developing and that there are currently no approved MDMA, psilocybin or MDMA-inspired products evaluated by the TGA for quality, safety and efficacy. It also notes that adverse effects can occur, and that the availability of these products depends on clinical trial outcomes.

Context From Earlier Disclosures

The release refers readers to earlier company disclosures for its trained therapist count, its June quarter activities report and the number of treatment beds across its five sites. Emyria presents the recruitment as a workforce step that supports its existing clinics, and it states that the expansion is intended to keep the clinical standards, patient safety and treatment outcomes that underpin its care models.

Looking Ahead

Executive Chair Greg Hutchinson said the company’s 2027 priority is making its treatments accessible across the country. The coming quarters will show whether the new therapists complete training on schedule and whether patient volumes rise as the company expects.